Table 1.
Time of diagnosis CRC Stage I–III (n = 157) | UKCTOCS cases (n = 97) | |||
---|---|---|---|---|
Sensitivity (%) | Sensitivity (%) | |||
Peptide | 95% specificity | 90% specificity | 95% specificity | 90% specificity |
MUC1 | 10.2 (16/157) | 19.7 (31/157) | 7.2 (7/97) | 17.5 (17/97) |
MUC1-Tn | 16.6 (26/157) | 35.7 (56/157) | 2.1 (2/97) | 11.4 (11/97) |
MUC1-STn | 42.0 (66/157) | 50.3 (79/157) | 8.2 (8/97) | 21.6 (21/97) |
MUC1-Core3 | 42.0 (66/157) | 48.4 (76/157) | 13.4 (13/97) | 23.7 (24/97) |
MUC1-Core3 + MU1-STn | 44.6 (70/157) | 59.9 (94/157) | 14.4 (14/97) | 21.6 (21/97) |
MUC1-STn + p53-10 + p53-25 | 20.4 (32/157) | 34.4 (54/157) | 24.7 (24/97) | 32.0 (31/97) |
MUC1-Core3 + p53-10 + p53-25 | 35.0 (55/157) | 44.0 (69/157) | 26.8 (26/97) | 41.2 (40/97) |
MUC1-Core3 + MUC1-STn + p53-10 + p53-25 | 47.8 (75/157) | 52.2 (82/157) | 32.0 (31/97) | 35.1 (34/97) |
MUC1-Core3 + MUC1-STn + p53-58 | 47.8 (75/157) | 59.9 (94/157) | 19.6 (19/97) | 25.8 (25/97) |
MUC1-Core3 + MUC1-STn + p53-43 | 54.8 (86/157) | 61.1 (96/157) | 23.7 (23/97) | 32.0 (31/97) |